ISAL 2019 | Use of gemtuzumab ozogamicin in CBF-AML

Name: Use of gemtuzumab ozogamicin in CBF-AML
Uploaded: 2019-03-01T15:42:53.000Z
Duration: 4 min 18 s
Description: Alan Burnett, MD, FRCP, of Cardiff University, Cardiff, UK, discusses the clinical development of gemtuzumab ozogamicin, focusing on its use in core binding factor (CBF) acute myeloid leukemia (AML) and the remaining questions in this field. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

Alan Burnett • 1 Mar 2019

ISAL 2019

Acute Myeloid Leukemia Leukemia Antibodies Cytarabine Gemtuzumab ozogamicin

Alan Burnett, MD, FRCP, of Cardiff University, Cardiff, UK, discusses the clinical development of gemtuzumab ozogamicin, focusing on its use in core binding factor (CBF) acute myeloid leukemia (AML) and the remaining questions in this field. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.